Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin.
about
Morphometric analysis of peri-implantation endometrium in patients having excessively high oestradiol concentrations after ovarian stimulation.Endocrine late effects after bone marrow transplant.The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.Ovarian stimulation for in vitro fertilization in patients with endometriosis.New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists.Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment.Use of oral contraceptives in infertile patients: A descriptive review.Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patientsIn vitro fertilization for endometriosis-associated infertility.Chapter 3 Current Challenges in Immature Oocyte Cryopreservation.The effect on pregnancy and multiples of transferring 1-3 embryos in women at least 40 years old.Does the duration of gonadotropin stımulation affect embryo quality on post-retrieval day 3?Clinical usefulness of basal FSH as a prognostic factor in patients undergoing intracytoplasmic sperm injection.Efficacy assessment of highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotropin during pituitary suppression in patients undergoing GIFT for unexplained infertility.Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate.Pituitary down-regulation in IVF cycles: is it necessary to use strict criteria?Low dose gonadotropin-releasing hormone agonist treatments with early discontinuation for controlled ovarian hyperstimulation in an in vitro fertilization program.
P2860
Q32067083-76A7543D-670B-4D80-BA4D-E26D91AB3CA9Q34722713-CA9CC97F-8B87-4455-A369-B9C207B33060Q35186161-201C015C-5A52-4DD0-902C-E3E030E2CD9DQ35821969-6A9C4D27-E971-404C-89A1-EFBACA082643Q36249876-89FF9DB0-B06F-47C2-9266-5C874514B8BCQ36268006-46611608-AE53-46CC-A580-FDC39F04FBC2Q36270562-C2E711E6-F21B-4F52-8088-AF2B4D90D8C5Q36668521-82285434-2959-48F4-A3AD-4267CBD235C7Q36970328-DEEBBFD7-432F-4B9C-8241-38103B899393Q38591186-D4E3D158-6A3F-45F3-8EA4-1026A2A56D10Q39249988-BD9EB028-1DC5-4899-86C3-F37745D9647DQ39721403-B982077B-A4CB-44C8-B266-45DD947842FDQ48697368-B376F269-89A8-4ED2-96C9-797C2EDD1990Q48892926-9F56E2E8-966A-423F-8434-0D664251A546Q48935296-EF45D98B-89CF-4B71-B994-49A57E59BF34Q49011969-5EDA9681-46F7-4E25-9865-3AB883022A98Q49037218-C2D70EC0-1E18-4D71-BB66-B1FECD0C2D1CQ55069292-83E0A3AF-52CD-4272-8644-705E55B7BF39
P2860
Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Cumulative conception and live ...... ing hormone agonist buserelin.
@en
type
label
Cumulative conception and live ...... ing hormone agonist buserelin.
@en
prefLabel
Cumulative conception and live ...... ing hormone agonist buserelin.
@en
P2093
P1476
Cumulative conception and live ...... ing hormone agonist buserelin.
@en
P2093
Brinsden P
Campbell S
Edwards RG
Maconochie N
P304
P356
10.1016/0002-9378(94)90291-7
P407
P577
1994-08-01T00:00:00Z